Company profile: Verve Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage genetic medicines for cardiovascular disease, including gene editing therapies VERVE-101 targeting PCSK9 to lower LDL-C in heterozygous familial hypercholesterolemia and ASCVD, and VERVE-201 targeting ANGPTL3 for homozygous and refractory hypercholesterolemia, enabled by a proprietary GalNAc-LNP liver delivery system, with medicines evaluated in clinical trials.
Products and services
- GalNAc-LNP Delivery System: A novel liver delivery technology developed for effective gene editing medicine delivery in patients with homozygous familial hypercholesterolemia
- VERVE-101: A clinical-stage gene-editing medicine that precisely targets the PCSK9 gene to lower LDL-C in patients with heterozygous familial hypercholesterolemia and established ASCVD
- VERVE-201: A proprietary gene-editing medicine that targets the ANGPTL3 gene for patients with homozygous familial hypercholesterolemia and refractory hypercholesterolemia, delivered via the GalNAc-LNP
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Verve Therapeutics
Epistem
HQ: United Kingdom
Website
- Description: Provider of specialist contract research services supporting drug discovery and development, offering preclinical in vitro/in vivo models in oncology, inflammatory and gastrointestinal diseases (incl. GI toxicities); GCLP-accredited clinical trial support (histology, IHC, image analysis, gene expression, DNA genotyping); organoid models; cancer stem cell sphere assays; subcutaneous xenografts; orthotopic/metastatic bioluminescent models.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epistem company profile →
Congenica
HQ: United Kingdom
Website
- Description: Provider of a clinical genomic diagnostic decision support platform. Sapientia integrates human DNA sequences with deep clinical phenotyping to enable actionable interpretation. Offerings include automated analysis for inherited diseases, somatic oncology, rare disease diagnosis, pathogen surveillance and pharma insights, upcoming pharmacogenomics, plus professional services for implementation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Congenica company profile →
Therion DNA
HQ: United States
Website
- Description: Provider of DNA-based testing services for animals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Therion DNA company profile →
Genomics
HQ: United Kingdom
Website
- Description: Provider of health-tech solutions leveraging genetic data to estimate disease risk, enable early detection, and support drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomics company profile →
Treos Bio
HQ: United Kingdom
Website
- Description: Provider of computational immunology solutions that predict in silico likely responders to cancer immunotherapies and design next-generation targeted immunotherapies tailored to patient genetics; offers PolyPEPI1018 for metastatic colorectal cancer (developed without need for tumor biopsy), PEPI Panel to create personalized therapies based on tumor type and HLA genotype, PolyPEPI-SCoV-2 preventive vaccine, and PEPI Test predicting peptide-specific T cell responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Treos Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Verve Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Verve Therapeutics
2.2 - Growth funds investing in similar companies to Verve Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Verve Therapeutics
4.2 - Public trading comparable groups for Verve Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →